Treatment options for hypertrophic cardiomyopathy are based primarily on the patient’s symptoms and risk of sudden cardiac death ratings. If the patient is asymptomatic, then the cardiomyopathy itself does not require treatment and most patients will have a near normal life expectancy, regardless of how severe the left ventricular outflow tract obstruction is. The treatment for such patients is mainly for other related diseases, such as hypertension, coronary artery disease, diabetes, hyperlipidemia and obesity; they can do low-intensity aerobic exercise and avoid strenuous exercise; and do a good assessment of the risk of sudden cardiac death and decide whether to install an internal automatic defibrillator (ICD) based on the assessment results. If the patient has symptoms, drug therapy is preferred; if drug therapy is not effective, surgical or medical interventional alcohol ablation therapy can be considered. If the effect of betablocker is unsatisfactory, calcium antagonist such as isoptin can be added. If the effect is still unsatisfactory, Dapsigargin can be used in combination. Avoid the application of vasodilators, high-dose diuretics, dopamine, dobutamine, norepinephrine and other drugs in the treatment; low blood pressure can be increased by applying phenylephrine. If drug treatment is not effective, surgical or medical interventional alcohol ablation treatment can be considered. Surgical procedure is mainly to remove the hypertrophic and stenotic myocardial tissue of the left ventricular outflow tract through an ascending aortic incision to relieve the left ventricular outflow tract obstruction. The success rate of both treatments is relatively high, and the long-term results of surgery are better, while the complication rate is also lower than that of interventional treatment. Therefore, surgery is currently the preferred invasive treatment method internationally. If none of the above methods is desired, pacemaker installation can be tried, although the efficacy needs to be further clarified. Finally, a risk assessment for sudden cardiac death should be performed regardless of whether the patient is symptomatic or not; if the assessment results show a high risk of sudden death, an intracorporeal automatic defibrillator (ICD) needs to be considered.